Skip to main content
Saniona logo

Saniona — Investor Relations & Filings

Ticker · SANION ISIN · SE0005794617 LEI · 549300XO4L9XNOCFCZ84 ST Manufacturing
Open in API
Filings indexed 298 across all filing types
Latest filing 2020-12-17 M&A Activity
Country SE Sweden
Listing ST SANION

About Saniona

http://saniona.com

Saniona is a clinical-stage biopharmaceutical company focused on the research and development of treatments for neurological disorders, with a primary emphasis on epilepsy. The company is a leader in the field of ion channel modulation, leveraging its expertise and a proprietary drug discovery engine to create new medicines. Saniona has developed an extensive library of over 20,000 proprietary molecules designed to target various ion channels. Its pipeline includes multiple potential new medicines advancing through clinical trials, with the goal of addressing unmet medical needs for patients with central nervous system diseases.

Recent filings

Filing Released Lang Actions
Saniona informerades idag att Novartis planerar förvärva Cadent Therapeutics, där Saniona har en ägarandel om cirka 3 procent
M&A Activity Classification · 95% confidence The document is a press release from Saniona regarding the acquisition of Cadent Therapeutics by Novartis. Since Saniona holds a 3% stake in Cadent, this is a corporate announcement regarding M&A activity involving an asset or investment of the company. It does not fit the criteria for a full report or a simple publication notice, but rather describes the impact and details of a merger/acquisition event.
2020-12-17 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 95% confidence The document is titled 'DELÅRSRAPPORT FÖR SANIONA AB (PUBL) Perioden Januari – september 2020' which translates to 'Interim Report for Saniona AB (Publ) Period January – September 2020'. It contains detailed financial key figures for the period January to September 2020 and Q3 2020, including net revenue, EBIT, earnings per share, and period results. It also discusses significant events during the third quarter and after the period, including capital raising, management changes, clinical trial updates, and strategic plans. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2020
2020-11-30 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 95% confidence The document is titled 'INTERIM REPORT FOR SANIONA AB (PUBL) Perioden January - September 2020' and contains detailed financial data for the first nine months of 2020, including net revenues, EBIT, net profit/loss, earnings per share, and business highlights for Q3 2020. It also discusses significant events after the reporting period, CEO comments, and detailed operational updates. The length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The presence of actual financial statements and substantive financial data for a period shorter than a full fiscal year (January to September 2020) aligns with the definition of an Interim / Quarterly Report (IR). Therefore, the document is best classified as an Interim / Quarterly Report (IR). 9M 2020
2020-11-30 English
Saniona AB’s Nomination Committee for the Annual General Meeting 2021
Regulatory Filings Classification · 95% confidence The document is a press release announcing the composition of the Nomination Committee for the upcoming Annual General Meeting (AGM) 2021. It details the members of the committee and their responsibilities regarding future board and auditor elections. Since this is a regulatory announcement regarding corporate governance and meeting preparation rather than the AGM presentation itself or a proxy statement, it falls under the category of general regulatory filings.
2020-11-26 English
Saniona AB:s valberedning inför årsstämman 2021
AGM Information Classification · 98% confidence The document is a press release announcing the composition of the nomination committee (valberedning) for the upcoming 2021 Annual General Meeting. It details the members of the committee and their appointment process, which is a standard corporate governance disclosure related to board preparation. Since it does not fit into specific financial reporting categories like 10-K or IR, and is not a proxy solicitation or a report publication announcement, it falls under the general regulatory announcement category for corporate governance and board-related updates.
2020-11-26 Swedish
Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity
Regulatory Filings Classification · 95% confidence The document is a press release from Saniona announcing positive topline results from a Phase 2 clinical trial (Tesomet). It details clinical trial data, safety, and efficacy endpoints, and mentions an upcoming webcast. This is a standard corporate announcement of clinical trial results, which falls under the category of Regulatory Filings (RNS) as it is a public disclosure of material information required by market abuse regulations.
2020-11-23 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.